NCT00682682

Brief Summary

Ultimately, the purpose of the present study is to help improve pain control in burn patients during wound care and physical therapy, where pain levels with opioids alone are often excessively high. This study measures how much virtual reality pain distraction reduces pain compared to traditional opioid pain meds, and whether there is additional pain reduction when Virtual Reality distraction + Opioids are combined. In addition to studying the amount of pain reduction, this study will also measure side effects (if any) of the two treatments (Virtual Reality pain distraction and Opioids) alone and when combined. Healthy volunteers will be recruited from advertisements will undergo a trial of the pain testing. They will receive a series of brief stimuli (at a painful but tolerable safe intensities they select and approve during baseline testing), separated by intervals of no pain. Participants will rate how much pain they felt after each brief stimulus, and will fill out side effects questionnaires after finishing the pain session. Subjects will participate in each of the four conditions in which the order is randomized.

  • No opioids (0ng/ml hydromorphone) + no virtual reality Snow World distraction
  • No opioids + yes virtual reality Snow World distraction
  • Moderate dose of pain medicine (4ng/ml hydromorphone) + no virtual reality
  • Moderate dose of pain medicine + yes virtual reality Snow World distraction It is our hypothesis that VR distraction + opioids will show a reduced perception of pain in subjects more than opioids alone or no intervention (control).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable pain

Timeline
Completed

Started Dec 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2007

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2008

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

May 20, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 22, 2008

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

September 13, 2011

Status Verified

September 1, 2011

Enrollment Period

5 months

First QC Date

May 20, 2008

Last Update Submit

September 12, 2011

Conditions

Keywords

Pain distractionAnalgesic interventionsBurn patients

Outcome Measures

Primary Outcomes (1)

  • Efficacy of VR distraction with and without opioid when pain stimulus is applied.

    at completion of study

Study Arms (1)

1

EXPERIMENTAL

all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid

Other: Virtual Reality video distractionOther: Virtual Reality video game

Interventions

Virtual Reality involves wearing a helmet and playing a game called "Snow world". This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are "in" the game.

1

Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being "in" the game. The game used for this study is "Snow World"

1

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men and women 18-45 years old
  • Normal height and weight ratio

You may not qualify if:

  • women who are pregnant and nursing
  • history of substance abuse
  • access to opioids in the workplace
  • smokes cigarettes
  • history of medical problems with the following: heart, lungs, liver, kidneys, endocrine, neurologic, migraines, or psychiatric requiring medical intervention
  • anemia
  • chronic pain
  • allergy or hypersensitivity to opioids, velcro, or latex
  • severe motion sickness
  • unusual sensitivity or lack of sensitivity to pain
  • sensitive skin or feet

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Washington

Seattle, Washington, 98195, United States

Location

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Samuel R. Sharar, MD

    Professor, University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Coordinator

Study Record Dates

First Submitted

May 20, 2008

First Posted

May 22, 2008

Study Start

December 1, 2007

Primary Completion

May 1, 2008

Study Completion

December 1, 2008

Last Updated

September 13, 2011

Record last verified: 2011-09

Locations